NeuroSense Therapeutics Ltd. Cash And Cash Equivalents At Carrying Value

Quick Answer

NeuroSense Therapeutics Ltd. reported Cash And Cash Equivalents At Carrying Value of $166.0 thousand for the year ending 2025.

  • NeuroSense Therapeutics Ltd. showed a decrease of -95.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from NeuroSense Therapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
  • XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2023 to 2025), NeuroSense Therapeutics Ltd.'s Cash And Cash Equivalents At Carrying Value has declined by 93.7%.
  • Historical annual values: Fiscal year 2025: $166.0 thousand | Fiscal year 2024: $3.38 million | Fiscal year 2023: $2.64 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: